Physician profile
Sam A Oryol
NPI 1184618993
$2,399.20
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $488.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $751.88 | 2019-2020 | |
| Allergan, INC. | $274.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $237.02 | 2019-2020 | |
| Abbvie INC. | $222.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.60 | 2019-2020 | |
| Lilly USA, LLC | $148.50 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $145.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.59 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $91.09 | 2019-2020 | |
| Amarin Pharma, INC. | $46.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $35.60 | 2019 | |
| Pfizer INC. | $16.50 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.17 | 2019 | |
| Novo Nordisk INC | $14.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Oryol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.